Population
Patients with unstable angina or undergoing percutaneous interventions
Design
Review
Authors
Loading...
Oral GP IIb/IIIa inhibitors lack clinical benefit; leaves open reasons for phase III failures and alternative antiplatelet strategies.
This review explores the development and phase III trial failures of oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban, providing insights into their lack of clinical benefit.
Anders et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: